FrancophonIA/ELRC3.0 huggingface dataset:
English: Zoledronic Acid Hospira must not be mixed with other infusion solutions and should be administered as a single intravenous solution in a separate infusion line.
Estonian: Zoledronic Acid Hospira't ei tohi segada teiste infusioonilahustega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
English: Uveitis, episcleritis, iritis
Estonian: Uveiit, episkleriit, iriit Teadmata** Skleriit ja paroftalmia
English: Table 2: Efficacy results (prostate cancer patients receiving hormonal therapy) Any SRE (+TIH)
Estonian: Tabel 2: Efektiivsustulemused (hormoonravi saavad prostata vähiga patsiendid) Kõik LST (+TIH)
English: Abdominal pain Musculoskeletal and connective tissue disorders Common:
Estonian: Lihas-skeleti ja sidekoe kahjustused Sage:
English: Zoledronic Acid Hospira must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
Estonian: Zoledronic Acid Hospira't ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonisüsteemi kaudu.
English: Cases of ONJ have been reported in the postmarketing setting for zoledronic acid.
Estonian: LONi juhtudest on teatatud ka zoledroonhappe turuletuleku järgselt.
English: Zoledronic Acid Hospira 4 mg/5 ml sterile concentrate IV
Estonian: Zoledronic Acid Hospira 4 mg/5 ml steriilne kontsentraat i.v.
English: Efficacy results are provided in Table 4.
Estonian: Efektiivsustulemuste kokkuvõte on toodud tabelis 4.
English: A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with Zoledronic Acid Hospira in patients with concomitant risk factors.
Estonian: Kaasuvate riskifaktoritega patsienditel on soovitatav enne ravi alustamist Zoledronic Acid Hospira'ga teha asjakohane hammaste läbivaatus koos ennetava hambaraviga ning individuaalne kasu-riski hindamine.
English: Zoledronic Acid Hospira is supplied as packs containing 1 vial.
Estonian: Zoledronic Acid Hospira on saadaval pakendites, milles on 1 viaal.
English: Uncommon Neck pain, musculoskeletal stiffness, joint swelling, muscle spasms, shoulder pain, musculoskeletal chest pain, musculoskeletal pain, joint stiffness, arthritis, muscular weakness
Estonian: Kaelavalu, lihas-skeleti jäikus, liigeste turse, lihasspasmid, õlavalu, lihas-skeleti valu rindkeres, lihas-skeleti valu, liigeste jäikus, artriit, lihasnõrkus
English: − The active substance of Zoledronic Acid Hospira is zoledronic acid.
Estonian: Zoledronic Acid Hospira toimeaine on zoledroonhape.
English: − To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic Acid Hospira concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution.
Estonian: Kuidas Zoledronic Acid Hospira't ette valmistada ja manustada - 4 mg zoledroonhapet sisaldava infusioonilahuse valmistamiseks lahjendage Zoledronic Acid Hospira kontsentraat (5 ml) 100 ml infusioonilahusega, mis ei sisalda kaltsiumi või muid bivalentseid katioone.
English: Talk to your doctor before you are given Zoledronic Acid Hospira: - if you are being treated with any medicine containing zoledronic acid, which is also the active substance of Zoledronic Acid Hospira (zoledronic acid is used in adult patients with certain types of cancer to prevent bone complications or to reduce the amount of calcium).
Estonian: Acid Hospira toimeaine (zoledroonhapet kasutatakse täiskasvanud patsientidel teatud tüüpi vähi puhul luustikuga seotud kõrvaltoimete vältimiseks või kaltsiumi annuse vähendamiseks).
English: Your doctor should do a blood test to check your kidney function before each dose of Zoledronic Acid Hospira.
Estonian: Teie arst peab enne iga Zoledronic Acid Hospira annuse manustamist tegema vereanalüüsi neerufunktsiooni kontrollimiseks.
English: Hypocalcaemia has been reported in patients treated with zoledronic acid.
Estonian: Zoledroonhapet saanud patsientidel on teatatud hüpokaltseemiast.
English: Table 1: Preparation of reduced doses of Zoledronic Acid Hospira 4 mg/100 ml solution for infusion
Estonian: Tabel 1: Vähendatud annusega lahuse valmistamine Zoledronic Acid Hospira infusioonilahusest kontsentratsiooniga 4 mg/100 ml
English: There was no accumulation of the active substance in plasma after multiple doses given every 28 days.
Estonian: Korduval manustamisel 28-päevase intervalliga ei täheldatud toimeaine kumuleerumist plasmas.
English: For storage conditions of the diluted solution for infusion, see section 6.3.
Estonian: Säilitamistingimused pärast ravimpreparaadi lahjendamist vt lõik 6.3.
English: Very rare Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction) and other anatomical sites including femur and hip
Estonian: Väga harv Väliskuulmekanali osteonekroos (bifosfonaatide klassi kõrvaltoime) ja osteonekroos teistes kehapiirkondades, sealhulgas puusa ja reieluu osteonekroos
English: Zoledronic Acid Hospira is supplied as packs containing one bag.
Estonian: Zoledronic Acid Hospira on saadaval pakendites, milles on üks kott.
English: Zoledronic acid should only be resumed when serum creatinine returns to within 10% of baseline.
Estonian: Ravi võib jätkata vaid siis, kui seerumi kreatiniinisisaldus ei erine rohkem kui 10% algväärtusest.
English: Only clear solution free from particles and discoloration should be used.
Estonian: Kasutada võib ainult selget lahust, mis ei sisalda osakesi ja mille värvus ei ole muutunud.
English: − Sleepiness
Estonian: Neerukahjustus
English: One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate).
Estonian: Üks viaal 5 ml kontsentraadiga sisaldab 4 mg zoledroonhapet (monohüdraadina).
English: - The other ingredients are mannitol, sodium citrate and water for injections.
Estonian: - Teised koostisosad on mannitool, naatriumtsitraat ja süstevesi.
English: Measurement of serum calcium before infusion of zoledronic acid is recommended for patients with Paget´s disease.
Estonian: Pageti tõvega haigetel on soovitav enne zoledroonhappe infusiooni mõõta seerumi kaltsiumisisaldust.
English: Zoledronic Acid Hospira is supplied as packs containing 1 bag.
Estonian: Zoledronic Acid Hospira on saadaval pakendites, milles on 1 kott.
English: oC.
Estonian: A.
English: No interaction studies with other medicinal products have been performed with zoledronic acid.
Estonian: Zoledroonhappega uuringuid koostoimete kohta teiste ravimitega ei ole läbi viidud.
English: Renal impairment has been observed in patients after a single administration, renal failure requiring dialysis or with a fatal outcome has rarely occurred in patients with underlying renal impairment or with any of the risk factors described above.
Estonian: Harvadel juhtudel on olemasoleva neerufunktsiooni halvenemise või ülalkirjeldatud riskiteguritega patsientidel täheldatud dialüüsravi nõudnud või surmaga lõppenud neerupuudulikkust.
English: Frequency categories are defined using the following convention: very common ( 1/10); common ( 1/100 to <1/10); uncommon ( 1/1,000 to <1/100); rare ( 1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Estonian: Esinemissageduse kategooriad on esitatud järgmise konventsiooni kohaselt: väga sage (≥ 1/10); sage (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100); harv (≥ 1/10 000 kuni < 1/1000); väga harv
English: How Zoledronic Acid Hospira is used
Estonian: Kuidas Zoledronic Acid Hospira't kasutada
English: Your doctor may recommend a dental examination before you start treatment with Zoledronic Acid Hospira.
Estonian: Teie arst võib soovitada teil enne Zoledronic Acid Hospira ravi alustamist käia hambakontrollis.
English: After dilution: From a microbiological point of view, the diluted solution for infusion should be used immediately.
Estonian: Pärast lahjendamist: Mikrobioloogilise saastatuse vältimiseks tuleb ravim kohe ära kasutada.
English: Aseptic techniques must be followed during preparation of the infusion.
Estonian: Infusioonilahuse ettevalmistamisel tuleb kasutada aseptilisi töövõtteid.
English: Treatment of TIH
Estonian: Jälgimine ravi ajal
English: Your doctor may ask you to undergo a dental examination before you start treatment with Zoledronic Acid Hospira.
Estonian: Teie arst võib paluda teil enne Zoledronic Acid Hospira'ga ravi alustamist käia hambakontrollis.
English: One ml concentrate contains 0.8 mg zoledronic acid (as monohydrate).
Estonian: Üks ml kontsentraati sisaldab 0,8 mg zoledroonhapet (monohüdraadina).
English: Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction) and other anatomical sites including femur and hip Renal and urinary disorders Common:
Estonian: Väliskuulmekanali osteonekroos (bisfosfonaatide klassiefekt) ja osteonekroos teistes kehapiirkondades, sealhulgas puusa ja reieluu osteonekroos
English: It also contains mannitol, sodium citrate and water for injections.
Estonian: See sisaldab ka mannitooli, naatriumtsitraati ja süstevett.
English: The adverse reactions ranked under headings of frequency, are presented in Table 7.
Estonian: Tabelis 7 on kõrvaltoimed loetletud esinemissageduse järgi.
English: Prevention of skeletal related events in patients with advanced malignancies involving bone:
Estonian: Luustikuga seotud tüsistuste vältimine luukude haarava kaugelearenenud pahaloomulise kasvajaga patsientidel:
English: Increases in serum creatinine also occur in some patients with chronic administration of zoledronic acid at recommended doses for prevention of skeletal related events, although less frequently.
Estonian: Patsiendil, kes on luustikuga seotud tüsistuste vältimiseks saanud pikemat aega soovitatud annuses zoledroonhapet, võib tõusta kreatiniini sisaldus seerumis, ehkki seda on esinenud harvem.
English: Zoledronic acid treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Estonian: Raske neerukahjustusega TIH patsientidel võib ravi zoledroonhappega alustada vaid pärast võimaliku riski/eeldatava kasu suhte hindamist.
English: The withdrawn amount of concentrate must be further diluted in 100 ml of sterile sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution.
Estonian: Vajaliku annuse valmistamiseks võetud kontsentraat tuleb lahjendada 100 ml steriilse naatriumkloriidi 9 mg/ml (0,9%) süstelahusega või 5% glükoosi lahusega.
English: Rare cases of renal failure requiring dialysis and rare cases with a fatal outcome have been reported in patients with pre-existing renal dysfunction or other risk factors such as advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, or dehydration in the post infusion period (see sections 4.4 and 4.8 Class effects)
Estonian: Neerufunktsiooni häire või teiste riskitegurite olemasolul - näiteks kõrge iga, teiste nefrotoksiliste ravimite samaaegne kasutamine, samaaegne ravi diureetikumidega või dehüdratsioon infusioonijärgsel perioodil (vt lõigud 4.4 ja lõik 4.8 „Ravimiklassi kõrvaltoimed“), on harvadel juhtudel teatatud ka dialüüsravi nõudnud või surmaga lõppenud neerupuudulikkusest
English: p-value
Estonian: Pole kohaldatav p-väärtus
English: − Skin reactions (redness and swelling) at the infusion site, rash, itching.
Estonian: - Nahareaktsioonid (punetus ja turse) infusioonikohas, nahalööve, sügelus.
English: You should not be given Zoledronic Acid Hospira if you are pregnant.
Estonian: Raseduse ajal ei tohi Zoledronic Acid Hospira't teile manustada.
English: Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia) Respiratory, thoracic and mediastinal disorders Uncommon: Dyspnoea, cough, bronchoconstriction Rare
Estonian: Bradükardia, südame arütmia (sekundaarne hüpokaltseemiale) Respiratoorsed, rindkere ja mediastiinumi häired Aeg-ajalt:
English: No dose adjustment is necessary in TIH patients with serum creatinine < 400 µmol/l or < 4.5 mg/dl (see section 4.4).
Estonian: Kliinilistest uuringutest arvati välja patsiendid, kelle seerumi kreatiniinisisaldus oli > 400 mikromol/l või > 4,5 mg/dl. Annuse kohandamine ei ole vajalik TIH patsientidel, kelle seerumi kreatiniinisisaldus on < 400 mikromol/l või < 4,5 mg/dl (vt lõik 4.4).
English: Mannitol, sodium citrate and water for injections.
Estonian: Mannitool, naatriumtsitraat ja süstevesi.
English: Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid (see section 4.4).
Estonian: Luuresorbtsiooni inhibeerivaid aineid (nagu zoledroonhape) sisaldavate ravimitega ravitud patsientidel, peamiselt vähihaigetel, on teatatud lõualuu osteonekroosi tekkest (vt lõik 4.4).
English: − Weight increase
Estonian: - Kehakaalu tõus.
English: VIAL LABEL
Estonian: KASUTUSJUHEND
English: − The other ingredients are: mannitol, sodium citrate, sodium chloride and water for injections.
Estonian: - Teised koostisosad on mannitool, naatriumtsitraat, naatriumkloriid ja süstevesi.
English: Cases of osteonecrosis of the jaw have been reported; predominantly in cancer patients treated with medicinal products that inhibit bone resorption, including zoledronic acid (see section 4.4).
Estonian: Luuresorptsiooni inhibeerivate ravimite, kaasa arvatud zoledroonhappega ravitud patsientidel, peamiselt vähihaigetel, teatatud lõualuu osteonekroosi tekkest (vt lõik 4.4).
English: − High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhea, constipation, abdominal pain, dry mouth.
Estonian: - Kõrge vererõhk, õhupuudus, pearinglus, ärevus, unehäired, maitsetundlikkuse häired, värinad,
English: Solution for infusion 4 mg/100 ml
Estonian: Infusioonilahus 4 mg/100 ml 1 intravenoosne kott
English: The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth.
Estonian: Uue bisfosfonaatide ravikuuri alustamist tuleb edasi lükata patsientidel, kellel on suuõõnes paranemata pehme koe kahjustused.
English: Very common (may affect more than 1 in 10 people):− Low level of phosphate in the blood.
Estonian: Väga harv (võivad esineda kuni ühel inimesel 10 000-st): - Madalast vererõhust tingitud minestus.
English: Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing) Uncommon: Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria
Estonian: Asteenia, perifeersed tursed, reaktsioonid süstekohal (sh valu, nahaärritus, turse, induratsioon), valu rindkeres, kehakaalu suurenemine, anafülaktiline reaktsioon/šokk, urtikaaria
English: − Chest pain.
Estonian: - Valu rinnus.
English: Prevention of skeletal related events in patients with advanced malignancies involving bone
Estonian: Luustikuga seotud tüsistuste vältimine luukude haarava kaugelearenenud pahaloomulise kasvajaga patsientidel
English: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease.
Estonian: Zoledroonhappe kasutamisel heakskiidetud näidustustel on kindlaks tehtud järgmised olulised riskid: neerufunktsiooni kahjustus, lõualuu osteonekroos, akuutse faasi reaktsioon, hüpokaltseemia, kodade virvendusarütmia, anafülaksia, interstitsiaalne kopsuhaigus.
English: Aseptic techniques must be followed during the preparation of the infusion.
Estonian: Infusiooni ettevalmistamisel tuleb kinni pidada aseptika reeglitest.
English: p-value Median time to SRE (days)
Estonian: Keskmine aeg LST-ni (päevades)
English: Tachycardia Respiratory, thoracic and mediastinal disorders Common:
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired Sage:
English: In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, reduced Zoledronic Acid Hospira doses are recommended (see also section 4.4).
Estonian: Kerge kuni keskmise raskusega neerukahjustusega luumetastaasidega patsientidele kreatiniini kliirensiga 30…60 ml/min on ravi alustamiseks soovitatavad järgmised madalamad Zoledronic Acid Hospira annused (vt ka lõik
English: A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported in the post-marketing setting in patients receiving zoledronic acid for osteoporosis.
Estonian: Zoledronic Acid Hospira't (zoledroonhape) osteoporoosi raviks saanud patsientidel on turuletulekujärgselt teatatud kõrvaltoimest, mida nimetatakse lõualuu osteonekroosiks (lõualuu kahjustus).
English: How to store Zoledronic Acid Hospira
Estonian: Kuidas Zoledronic Acid Hospira't säilitada
English: Blood creatinine and blood urea increased, hypocalcaemia Uncommon: Hypomagnesaemia, hypokalaemia Rare:
Estonian: Kreatiniini ja uurea sisalduse tõus veres, hüpokaltseemia
English: Other products containing zoledronic acid as active substance are available for osteoporosis indications and treatment of Paget´s disease of the bone.
Estonian: Osteoporoosi näidustusel ja Pageti luutõve raviks on saadaval teisi toimeainena zoledroonhapet sisaldavaid preparaate.
English: − Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite.
Estonian: - Seedetrakti häired, nt iiveldus, oksendamine ja isukaotus.
English: Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Estonian: 4 mg zoledroonhapet uuriti topeltpimedas, randomiseeritud platseebokontrolliga uuringus, mis hõlmas 228 patsienti, kelle puhul rinnanäärmevähi metastaaside esinemine luukoes oli dokumenteeritud.
English: You should not be given Zoledronic Acid Hospira:
Estonian: Imetamise ajal ei tohi Zoledronic Acid Hospira't teile manustada.
English: • Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each Zoledronic Acid Hospira dose.
Estonian: - Enne igakordset Zoledronic Acid Hospira annuse manustamist tuleb Cockcroft-Gault'i valemi järgi arvutada kreatiniini kliirens vastavalt patsiendi tegelikule kehakaalule.
English: Other products containing zoledronic acid as active substance are available for oncology indications.
Estonian: Onkoloogilistel näidustusel on saadaval teisi toimeainena zoledroonhapet sisaldavaid preparaate.
English: The hydration status of patients must be assessed prior to and following administration of zoledronic acid to ensure that they are adequately hydrated.
Estonian: Enne ja pärast zoledroonhappe manustamist tuleb kontrollida, kas patsient on piisavalt hüdreeritud.
English: Table 4: Efficacy results (breast cancer and multiple myeloma patients) Any SRE (+TIH)
Estonian: Tabel 4: Efektiivsustulemused (hulgimüeloomi ja rinnanäärmevähiga patsiendid) Kõik LST (+TIH)
English: − The active substance of Zoledronic Acid Hospira 4 mg/100 ml solution for infusion is zoledronic acid.
Estonian: Mida Zoledronic Acid Hospira sisaldab - Zoledronic Acid Hospira 4 mg/100 ml infusioonilahuse toimeaine on zoledroonhape.
English: Adequate calcium and vitamin D intake are recommended in association with Zoledronic Acid Hospira administration.
Estonian: Zoledronic Acid Hospira'ga ravi ajal on soovitatav kasutada piisavas koguses kaltsiumi ja D-vitamiini preparaate.
English: − The other ingredients are: mannitol, sodium citrate, water for injections.
Estonian: - Teised koostisosad on mannitool, naatriumtsitraat, süstevesi.
English: •Breast-feeding (see section 4.6).
Estonian: - Imetamine (vt lõik 4.6).
English: • Monitoring of serum creatinine should be considered in at-risk patients.
Estonian: - Vastava riskiga patsientidel tuleb kaaluda vere kreatiniinisisalduse jälgimist.
English: Cardiac arrhythmias and neurologic adverse events (including convulsions, hypoaesthesia and tetany) have been reported secondary to cases of severe hypocalcaemia.
Estonian: Raske hüpokaltseemia puhul on sekundaarselt teatatud südame arütmiast ning neuroloogilistest kõrvaltoimetest (sh krambid, hüpoesteesia ja tetaania).
English: Zoledronic Acid Hospira contains the active substance zoledronic acid.
Estonian: Mida Zoledronic Acid Hospira sisaldab - Toimeaine on zoledroonhape.
English: Uncommon: Acute renal failure, haematuria, proteinuria Rare
Estonian: Äge neerupuudulikkus, hematuuria, proteinuuria
English: Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4).
Estonian: Pärast 4 mg zoledroonhappe algannuse või ühekordse annuse manustamist on patsientidel teatatud neerufunktsiooni halvenemisest, mis progresseerus kuni neerupuudulikkuse ja dialüüsivajaduseni (vt lõik 4.4).
English: Zoledronic Acid Hospira 4 mg/100 ml solution for infusion
Estonian: Zoledronic Acid Hospira 4 mg/100 ml infusioonilahus
English: Table 3: Efficacy results (solid tumours other than breast or prostate cancer) Any SRE (+TIH)
Estonian: Tabel 3: Efektiivsustulemused (soliidtuumoritega patsiendid, v.a. rinnanäärme- või prostatavähk) Kõik LST (+TIH)
English: The adverse reactions ranked under headings of frequency, are presented in Table 6.
Estonian: Tabelis 6 on kõrvaltoimed loetletud esinemissageduse järgi.
English: Efficacy results are provided in Table 5.
Estonian: Uuringu tulemused on kokku võetud tabelis 5.
English: − if you are allergic (hypersensitive) to zoledronic acid, another bisphosphonate (the group of substances to which zoledronic acid belongs), or any of the other ingredients of Zoledronic Acid Hospira (listed in section 6).
Estonian: Teile ei tohi manustada Zoledronic Acid Hospira't: - kui toidate last rinnaga; - kui olete zoledroonhappe, mõne teise bisfosfonaadi (ravimigrupp, millesse zoledroonhape kuulub) või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia.
Estonian: Raske hüpokaltseemia puhul on sekundaarselt teatatud ebaregulaarsest südamerütmist (südame arütmia), krampidest, spasmist ning tõmblustest (tetaania).
English: ONJ has been reported in the post-marketing setting in patients receiving zoledronic acid for osteoporosis (see section 4.8).
Estonian: Zoledroonhappega osteoporoosiravi saanud patsientidel on kliinilistes uuringutes ja turuletulekujärgselt teatatud lõualuu osteonekroosist (vt lõik 4.8).
English: Zoledronic Acid Hospira 5 mg/100 ml solution for infusion
Estonian: Zoledronic Acid Hospira 5 mg/100 ml infusioonilahus
English: Each bag of 100 ml contains 5 mg zoledronic acid (as monohydrate).
Estonian: Üks 100 ml kott sisaldab 5 mg zoledroonhapet (monohüdraadina).
English: − Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis.
Estonian: - Zoledroonhappe manustamise korral postmenopausaalse osteoporoosi raviks on patsientidel täheldatud südame rütmihäireid (kodade virvendusarütmia).
English: How to prepare and administer Zoledronic Acid Hospira
Estonian: Kuidas Zoledronic Acid Hospira't ette valmistada ja manustada
English: Table 4: Efficacy results (solid tumours other than breast or prostate cancer) Any SRE (+TIH)
Estonian: Tabel 4: Efektiivsustulemused (soliidtuumoritega patsiendid, v.a. rinnanäärme- või prostatavähk) Kõik LST (+TIH)
English: Zoledronic Acid Hospira 4 mg/100 ml solution for infusion Zoledronic acid
Estonian: Zoledronic Acid Hospira 4 mg/100 ml infusioonilahus Zoledroonhape
English: One ml solution contains 0.05 mg zoledronic acid (as monohydrate).
Estonian: Üks ml lahust sisaldab 0,05 mg zoledroonhapet (monohüdraadina).